Novartis and Johnson & Johnson to deprive Europeans of their right to Health

Novartis-Logo (1)

It was the last day of January that the European Commission decided to send a formal complaint against two pharmaceutical giants, Johnson and Johnson and Novartis, over an illegal secret deal that made European cancer patients suffer while it brought huge profits to the American and Swiss multinational accordingly.

After the meticulous research of DG Competition, that as usually, took around 10 years to bear fruit, it has been uncovered that the two of the three biggest Pharmaceutical companies of the world according to Forbes, were having a small party in Netherlands between 2005 and 2006 at the expense of the Dutch cancer patient. According to DG Comp, what was happening back then is that the Dutch branch of Johnson & Johnson in the Netherlands, Janssen-Cilag, had in its payroll for one year and a half a competitive pharmaceutical company specialized in generics called Sandoz. The latter is a proper known unit of the Swiss company Novartis. So, basically, Johnson and Johnson were paying to Novartis a huge amount of money for 17 months. Isn’t that weird? Competitor companies are supposed to have endless board meetings on how to steal money from each other and not sharing bribes. Was 2005 the year that the management of the two powerful companies lost their minds due to burnout?

The Pay for Delay Deal

Well, think again! These people knew very well what they were doing. We are talking here about the anticompetitive bad practice of Pharmaceuticals called “Pay for Delay” where one brand name is bribing the generic drug competitor in order to delay the release of the cheaper generic drug in the market. In our case the generic drug that was deliberately and illegally delayed to launch in the Dutch market is Fentanyl and it is a drug that is mainly used by cancer patients to relieve pain. In a nutshell, these two companies deprived the Dutch cancer patients from the right to be able to buy a much cheaper drug, so that they can save millions of Euros by preventing a market share loss that a cheaper substitute product in the market would bring.

On the antitrust statement of DG Competition on the 31st of January, Mr. Almunia, the EU Competition Commissioner, said: “If our preliminary conclusions are confirmed, the Dutch subsidiaries of Johnson & Johnson and Novartis entered into a so-called “co-promotion” agreement to avoid competing against each other, depriving users of fentanyl in the Netherlands from access to a cheaper pain killer,”… “The commission is determined to fight undue delays in the market entry of generic medicines so that European citizens have access to affordable health care”. The Basque EU Commissioner says it here very well, but he certainly cannot say anything to the Dutch patients that were not given the alternative of cheap Fentanyl for 17 monhts! Can he?

DG Comp is doing Fundraising

Unfortunately, it seems that this antitrust statement can serve only in two things: a) make impression and b) make the Commission richer. If the Commission wins this battle with the pharmaceutical dinosaurs, which we all hope it will, the only benefit will be a few billion Euros for DG Comp. And of course we live in crisis and Mr. Almunia needs to play the role of the Fundraiser but in the end of the day this will not solve the Pay for Delay syndrome that is expanding like a plague in Europe and is menacing significantly public health. I mean, what is 7 billion euros for Johnson and Johnson to pay as fine compared to the millions or billions that the company has probably saved by exercising this anticompetitive covert technique? And of course, we are talking here about one case that goes back 10 years ago and was uncovered now. Who knows how many other similar incidents we had or we have at this moment in Europe happening at the expense of the European citizen, which will never see the light of publicity? Hence, the culminant question here is: What next? How can the European citizen be sure that this kind of corporate bribing will not be repeated in the future?

The European Parliament had an idea

Only a week after the antitrust statement, a new draft law was voted on the 6th of February in the European Parliament that seems relevant to the topic of this story. The basic concept behind that is that European patients should be able to buy cheaper generic medicines. This is an excellent concept. The European Sting and all Europeans welcome this spirit from the European law makers without a doubt. However, the European Parliament only voted in favour of some new deadlines and transparency standards on pricing and reimbursement of generic medicines. As usually, all this will be addressed to the 27 member states.

Of course, this is something that Europe needed to have anyway, because the rules that are now in action and describe these procedures are almost 25 years old (1989). It is true that the procedures were poorly defined and slow while, as Mrs. Antoniya Parvanova, rapporteur from the Alliance of Liberals and Democrats for Europe (ALDE), said, sometimes it took a country up to 700 days to make decisions on pricing and reimbursement of medicines. However, why was this matter brought up in the European Parliament now and not before? Is it to take the next step after Mr. Almunia’s antitrust statement?

I am afraid not. The reasons are twofold:

a)      This vote apparently is not going to stop Pharmaceuticals to pay for delay

b)      The draft law was voted on the 6th of February, when on the 4th was the World Cancer Day. The period that the draft law was voted was a period with numerous events aiming at cancer awareness all around the world. Is it a coincidence that the flash addicted European Parliament voted for this in the beginning of February and not in March?

Overall the draft law is a good reform addressed to member states to improve the European health system as a whole but let’s be honest here. Big Pharmaceuticals will be still free out there to sign golden deals under the table with generic competitors, in order to delay the launch of their product so that they keep the prices and profits high for themselves. Who will touch these people? Or better who can touch these people? Is a few billion fine enough to make them stop?

I guess not. The only cure from this cancer is that the patient, the European citizen, is aware of what exactly is happening behind her back and I hope that with this story the Sting has contributed to that.

Advertising

Advertising

Advertising

Advertising

Advertising

the European Sting Milestones

Featured Stings

Stopping antimicrobial resistance would cost just USD 2 per person a year

European banking stress tests 2014: A more adverse approach for a shorter banking sector

The Japanese idea of ‘chowa’ – and how Asia can thrive in the future

We need to talk about how we define responsibility online – and how we enforce it

Big impact vs big exit: the social side of the start-up game presented at the WSA Global Congress in Vienna

What you need to know about the Sustainable Development Impact Summit

EU and China to do more in common if the global scene gets worse

Why Eurozone’s problems may end in a few months

Modern society has reached its limits. Society 5.0 will liberate us

Artificial Intelligence has a gender problem. Here’s what to do about it

The Commission tries to stop the ‘party’ with the structural funds

EU-Western Balkans summit in Sofia

This new way of understanding disease is changing medicine

7 amazing ways artificial intelligence is used in healthcare

“The Sea is vast as it admits all rivers”, Ambassador Yang Yanyi of the Chinese Mission to EU gives her farewell address in Brussels

Online radio and news broadcasts: Parliament and Council reach deal

Fragile countries risk being ‘stuck in a cycle of conflict and climate disaster,’ Security Council told

US-China trade war: Washington now wants control of the renminbi-yuan

Climate change and health: public health awareness in an international framework

Climate Change : An Already Health Emergency

In Gaza, UN envoy urges Israel, Palestinian factions to step back from brink of a war that ‘everybody will lose’

Will Eurozone be able to repay its debts? Is a bubble forming there?

EU readies for eventual annulment of the Turkish agreement on immigrants-refugees

EU Top Jobs summit ended with no agreement: welcome to Europe’s quicksand!

2016 crisis update: the year of the Red Fire Monkey burns the world’s markets down

2030 development agenda: Major breakthrough for world of work

Youth unemployment: No light at the end of the tunnel

Somalia has ‘once in a generation’ gender equality opportunity – UN Women chief

A Valentine’s Special: we can never overdose on love

EU Leaders’ meeting in Sofia: Completing a trusted Digital Single Market for the benefit of all

Merkel, Mercedes and Volkswagen to abolish European democracy

EU Commission: Banking and energy conglomerates don’t threaten competition!

THE ROAD TO GANESHA

Italy can stand the US rating agencies’ meaningless degrading

Cyprus banks under scrutiny

Fed, ECB take positions to face the next global financial crisis; the Brits uncovered

These charts show where the world’s refugees came from in 2017 – and where they’re heading

EU to spend €6 billion on youth employment and training futile schemes

Eurozone: There is a remedy for regional convergence

To win combat against HIV worldwide, ‘knowledge is power’, says UNAIDS report

Energy Union: EU invests a further €800 million in priority energy infrastructure

Measuring consumer confidence isn’t useful anymore. Here’s what we should do instead

COP21 Breaking News_10 December: UN Climate Chief Calls for Final Push to Meet Adaptation Fund Goal Very Close to Target

While EU Open Days 2013 discuss the 2020 strategy, Microsoft shares a glimpse of EU 2060

How can we build a workforce for our digital future?

Environment Committee MEPs vote to upgrade EU civil protection capacity

A Sting Exclusive: “Junior Enterprises themselves carry out projects focusing on the environment”, JADE President Daniela Runchi highlights from Brussels

Economy on a steady rise in Latin America and Caribbean region ‘despite international turbulence’ – UN report

Dramatic funding shortages a ‘severe catastrophe’ for people of Gaza: UN Coordinator

Frontline workers vaccinated in Uganda over Ebola fears, as top UN officials visit outbreak epicentre in DR Congo

Millions more migrant workers, means countries lose ‘most productive part’ of workforce

Girls groomed for suicide missions fight back against the extremists of Lake Chad

India’s economy is an ‘elephant that is starting to run’, according to the IMF

The right approach to addressing overcapacity problem from a Chinese perspective

Berlin favours economic and social disintegration in certain Eurozone countries

EU Commission spends billions without achieving targets

“Prevention is better than cure”: the main goal of modern medicine

More than 90% of the world’s children are breathing toxic air

Infrastructure around the world is failing. Here’s how to make it more resilient

Commission launches new tool to support digital teaching and learning in schools

Big world banks to pay $ 4.95bn for cheating customers; Is it a punishment or a gentle caress?

More Stings?

Comments

  1. I believe this is one of the so much important information for me.
    And i’m satisfied studying your article. But wanna
    remark on few basic things, The site style is perfect, the articles is in point of fact excellent : D.
    Just right task, cheers

Speak your Mind Here

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s